Key Developments: Allergan Inc (AGN)

AGN on New York Consolidated

213.89USD
28 Nov 2014
Price Change (% chg)

$-0.11 (-0.05%)
Prev Close
$214.00
Open
$214.09
Day's High
$214.64
Day's Low
$213.56
Volume
869,813
Avg. Vol
2,896,806
52-wk High
$214.64
52-wk Low
$94.98

Search Stocks

Latest Key Developments (Source: Significant Developments)

FDA approves new styles of Allergan Inc's NATRELLE 410 highly cohesive anatomically shaped silicone-filled breast implants
Wednesday, 12 Nov 2014 04:50pm EST 

Allergan Inc:Receives approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery.  Full Article

Allergan Inc declares third quarter dividend
Monday, 27 Oct 2014 07:00am EDT 

Allergan Inc:Declared a third quarter dividend of $0.05 per share, payable on Dec. 11 to stockholders of record on Nov. 20.  Full Article

Allergan Inc gives Q4 2014 EPS guidance above analysts' estimates; updates FY 2014 revenue guidance and raises FY 2014 EPS guidance
Monday, 27 Oct 2014 07:00am EDT 

Allergan Inc:Expects Q4 2014 total product net sales between $1.845 bln and $1.920 bln.Expects Q4 2014 non-GAAP diluted EPS attributable to stockholders between $1.80 and $1.83.Expects FY 2014 total product net sales between $7.080 bln and $7.155 bln.Expects FY 2014 non-GAAP diluted EPS attributable to stockholders between $6.27 and $6.30.Q4 2014 revenue of $1.867 bln and EPS of $1.74 - Thomson Reuters I/B/E/S.FY 2014 revenue of $7.15 bln and EPS of $6.12 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc raises Q3, FY 2014, FY 2015, FY 2016 EPS outlook; updates on Q3, FY 2014 revenue outlook to a range above analysts' estimates
Thursday, 9 Oct 2014 06:45am EDT 

Allergan Inc:Expects Q3 2014 non-GAAP diluted EPS attributable to stockholders to be between $1.76 and $1.78, as compared to previous range of $1.44 and $1.47.Expects Q3 2014 product net sales to increase in excess of 17 pct in dollars compared to product net sales Q3 2013.Expects FY 2014 non-GAAP diluted EPS attributable to stockholders to be between $6.20 and $6.25.Expects FY 2014 product net sales to increase between 14 and 15 pct in dollars compared to product net sales for FY 2013.Expects FY 2015 non-GAAP diluted EPS attributable to stockholders to be about $8.60.Expects FY 2016 non-GAAP diluted EPS attributable to stockholders to be about $10.25.Reported revenue of $1.558 bln in Q3 2013 and revenue of $6.300 bln in FY 2013.Q3 2014 EPS of $1.48, revenue of $1.736 bln - Thomson Reuters I/B/E/S.FY 2014 EPS of $5.81, revenue of $7.087 bln - Thomson Reuters I/B/E/S.FY 2015 EPS of $8.25 - Thomson Reuters I/B/E/S.FY 2016 EPS of $9.82 - Thomson Reuters I/B/E/S.  Full Article

Allergan Inc announces FDA approval revised indication for OZURDEX
Monday, 29 Sep 2014 09:00am EDT 

Allergan Inc:Says the U.S. Food and Drug Administration (FDA) has approved OZURDEX (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME).OZURDEX was originally approved in June as a treatment for DME in adult patients who have an artificial lens implant (pseudophakic) or who are scheduled for cataract surgery (phakic).Based on ongoing review of clinical data demonstrating efficacy and safety, the FDA has now approved OZURDEX for use in the general DME patient population.  Full Article

Allergan Inc gives FY 2016 EPS guidance above analysts' estimates
Monday, 29 Sep 2014 08:00am EDT 

Allergan Inc:Expects to generate compounded annual adjusted EPS growth of more than 20 percent, which translates into $10.00 per share of adjusted EPS in FY 2016.FY 2016 EPS of $9.72 - Thomson Reuters I/B/E/S.  Full Article

Pershing Square Capital Management LP, Valeant Pharmaceuticals International Inc and Allergan Inc settle pending litigation before Delaware Court of Chancery
Tuesday, 16 Sep 2014 01:39am EDT 

Pershing Square Capital Management LP and Valeant Pharmaceuticals International Inc:Announce agreement with Allergan Inc to settle pending litigation before Delaware Court of Chancery.Pursuant to settlement, Allergan has agreed to unconditionally call and hold special meeting of its shareholders on Dec. 18, 2014.Shareholders of record at close of business on Oct. 30, will be entitled to receive notice of and vote at meeting.Shareholders who submitted special meeting requests will not be required to provide updated information to the company in advance of meeting.Pershing Square has delivered requests calling for special meeting from 51 institutions representing 35.68 pct. of outstanding common stock of Allergan.  Full Article

Allergan Inc reaffirms FY 2016 EPS guidance
Thursday, 11 Sep 2014 08:30pm EDT 

Allergan Inc:Estimates FY 2016 EPS at about $10.00.  Full Article

Allergan announces OZURDEX approved in European Union for Treatment of Diabetic Macular Edema
Tuesday, 2 Sep 2014 08:00am EDT 

Allergan Inc:Says the European Commission has extended Marketing Authorization for OZURDEX((reg))(dexamethasone 700 mcg intravitreal implant in applicator).To treat adult patients with visual impairment due to diabetic macular edema (DME) who are pseudophakic, or who are considered insufficiently responsive to, or unsuitable for non-corticosteroids therapy.DME is common complication with diabetes and is cause of sight loss in patients with diabetes.(2,3,4).Safety and efficacy of OZURDEX((reg))in the management of patients with DME was assessed in the MEAD (Macular Edema: Assessment of Implantable Dexamethasone in Diabetes) clinical trial program.(1,5).MEAD consisted of two multi-center 3-year sham-controlled, masked, randomized clinical studies assessing the proportion of patients with 15 or more letters improvement in best-corrected visual acuity (BCVA) from baseline.Developed for treatment of retinal disease, OZURDEX((reg))implant uses proprietary innovative NOVADUR((reg))solid polymer delivery system - a biodegradable implant that releases medicine over an extended period of time - to suppress inflammation, which plays key role in the development of DME.OZURDEX((reg))is already available throughout European Union as treatment licensed for macular edema in patients with retinal vein occlusion (RVO) and for inflammation of the posterior segment of eye characterized as non-infectious uveitis.  Full Article

Allergan Inc to request California Federal Court block valeant and pershing square from voting shares acquired in violation of insider trading laws
Tuesday, 26 Aug 2014 07:53pm EDT 

Allergan Inc:Says that it has asked the United States District Court for the Central District of California to set an expedited schedule for discovery and a motion for a preliminary injunction.Says injunction against Valeant Pharmaceuticals, Pershing Square Capital Management, L.P. and its principal, William A. Ackman, for violations of the federal securities laws.Says in addition, Allergan announced that it will hold a Special Meeting of Stockholders on Dec. 18, 2014.Allergan has established an Oct. 27, 2014 record date for stockholders entitled to vote at the Special Meeting.  Full Article

Photo

Ackman's Pershing Square sees big payoff from Allergan deal

BOSTON - Hedge fund mogul William Ackman told investors they could see a $6 billion payday when he closes the chapter on Allergan Inc., his firm's biggest bet of 2014.

Search Stocks